Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 18
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Welgene Biotech Co.,Ltd. provides genetic testing services. The company offers research services, including sequencing, microarray, qPCR verification, nucleic acid extraction/QC, LCM single cell experiment, and bioinformatics analysis services; and Cytoscan, an array-based comparative genomic hybridization. It also provides reagents, consumable supplies, and instruments, as well as software services. The company was founded in 2003 and is based in Taipei City, Taiwan.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITDA, overval
Data is available to registered users only
